Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HUMATIN vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
Hepatic coma (adjunctive therapy to reduce ammonia-forming bacteria in the gut),Diarrhea caused by enteropathogenic bacteria (e.g., Shigella, E. coli, Salmonella, Proteus, Staphylococcus, Pseudomonas aeruginosa)
Topical treatment of bacterial infections of the skin and eye (e.g., conjunctivitis, keratitis, blepharitis),Prophylaxis of minor wounds, cuts, and abrasions
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
Minimally absorbed from the gastrointestinal tract; systemically absorbed drug undergoes minimal hepatic metabolism.
Not systemically absorbed after topical administration; no significant metabolism.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
0% (negligible binding due to high polarity and minimal absorption)
Neomycin: 0-20%; polymyxin B: 60-80% (alpha-1-acid glycoprotein, albumin); bacitracin: <5%. Combined: ~40-50% bound overall.
0.2 L/kg (reflects limited distribution to extracellular fluid in absorbed fraction; primarily confined to GI tract)
Neomycin: ~0.25 L/kg; polymyxin B: ~0.5 L/kg; bacitracin: ~0.3 L/kg. Combined Vd ~0.3-0.5 L/kg, reflecting limited distribution mainly to extracellular fluid.
Oral: ~1% (ranges 0.5-1.5% due to poor absorption from gastrointestinal tract)
Topical/ophthalmic/otic: negligible systemic absorption (<0.1%).
Reduce dose and/or extend interval based on Cr Cl: Cr Cl 50-90 m L/min: 60-90% of dose; Cr Cl 10-50 m L/min: 30-60% of dose; Cr Cl <10 m L/min: 20-30% of dose.
No systemic absorption with typical topical use; no adjustment necessary. For extensive use on damaged skin, monitor renal function and adjust if needed; no specific GFR-based guidelines.
No specific Child-Pugh based adjustments; caution in severe hepatic impairment due to potential nephrotoxicity.
No adjustment needed for topical use. No systemic effects expected.
For hepatic coma: 15-25 mg/kg/day orally in 4 divided doses; for infectious diarrhea: 50 mg/kg/day orally in 4 divided doses, max 4 g/day.
Same as adult dosing for topical use. For neonates, use with caution on large surface areas; avoid prolonged use.
Adjust based on renal function; monitor for nephrotoxicity and ototoxicity; consider lower initial doses due to age-related renal decline.
No specific age-related adjustments. Use with caution on fragile skin; apply sparingly to avoid systemic absorption.
No FDA black box warning.
None.
Ototoxicity (mainly with prolonged use or renal impairment),Nephrotoxicity,Neuromuscular blockade (use caution in patients with myasthenia gravis or receiving neuromuscular blocking agents),Superinfection with resistant organisms,Use in renal impairment may increase risk of toxicity,Not for systemic infections (poor absorption)
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Neomycin is ototoxic and nephrotoxic if absorbed systemically (e.g., applied to large areas of damaged skin).,Avoid contact with eyes other than for ophthalmic use.,Cross-allergenicity among aminoglycosides exists.
Hypersensitivity to paromomycin or other aminoglycosides,Intestinal obstruction,Severe ulcerative bowel lesions
Hypersensitivity to any component of the product.,Otic use if tympanic membrane is perforated (risk of ototoxicity).
No significant food interactions. Administer with meals to minimize gastrointestinal irritation.
No known food interactions with topical application.
FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. However, potential benefits may warrant use in pregnant women despite potential risks. Aminoglycosides can cause fetal harm when administered to a pregnant woman, including ototoxicity and nephrotoxicity. Paromomycin is poorly absorbed after oral administration, so systemic exposure is minimal. Risk is considered low, but caution is advised.
No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No known association with congenital anomalies.
It is not known whether paromomycin is excreted in human milk after oral administration. Paromomycin is minimally absorbed systemically, so exposure to breastfed infants is expected to be low. However, because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: Not available.
Minimal systemic absorption suggests negligible excretion into breast milk; M/P ratio not determined. Considered compatible with breastfeeding by AAP; avoid application to breast area to prevent infant ingestion.
No dose adjustment is required during pregnancy. Paromomycin is poorly absorbed orally, and its pharmacokinetics are not significantly altered in pregnancy. However, caution is advised in patients with renal impairment or inflammatory bowel disease due to potential increased absorption.
No dosage adjustment required for topical use; systemic absorption is negligible. Use standard dosing as per non-pregnant adults.
Humatin (paromomycin) is an aminoglycoside antibiotic used primarily for intestinal amebiasis and hepatic coma. For hepatic coma, use as short-term adjunctive therapy; monitor for ototoxicity and nephrotoxicity, especially in renal impairment. Oral absorption is poor, so systemic toxicity is rare except with ulcerative bowel disease. Administer with food to reduce GI upset.
OTC triple antibiotic ointment; avoid use on deep wounds, puncture wounds, or animal bites due to risk of toxicity and lack of efficacy. Neomycin carries the highest risk of allergic contact dermatitis among topical antibiotics; consider patch testing if prolonged use needed. Polymyxin B can cause neurotoxicity and nephrotoxicity if applied to large wounds or damaged skin. Not for use in eyes, ears, or mucous membranes. Do not exceed 7 days of continuous use.
Take this medication exactly as prescribed, with food to lessen stomach upset.,Complete the full course of therapy even if you feel better.,Drink plenty of fluids to maintain hydration.,Report any hearing loss, ringing in ears, dizziness, or changes in urine output immediately.,May cause diarrhea; notify your doctor if severe or persistent.
Clean the affected area before applying a thin layer of ointment 1-3 times daily.,Do not use on large areas of skin, deep cuts, puncture wounds, or animal bites unless directed by a doctor.,Do not apply to eyes, nose, mouth, or inside ears.,Stop use and consult a doctor if rash or allergic reaction develops, condition worsens, or persists for more than 7 days.,Keep out of reach of children; seek medical attention if accidentally ingested.
No interactions on record
"Cisatracurium, a non-depolarizing neuromuscular blocking agent (NMBA), competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, causing skeletal muscle paralysis. Polymyxin B, a polypeptide antibiotic, can potentiate this neuromuscular blockade by reducing presynaptic acetylcholine release and stabilizing postsynaptic membranes, leading to prolonged and enhanced neuromuscular blockade. This interaction increases the risk of prolonged muscle paralysis, respiratory depression, and apnea, especially in patients with renal impairment or those receiving other NMBAs."
"Mecamylamine, a ganglionic blocking agent, potentiates the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic. This interaction occurs through additive or synergistic inhibition of neuromuscular transmission, potentially leading to prolonged or intensified muscle relaxation, respiratory depression, and apnea. The clinical outcome may include enhanced toxicity, especially in patients with renal impairment or those receiving concurrent anesthetics or other neuromuscular blocking agents."
"Decamethonium, a depolarizing neuromuscular blocker, enhances the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic that can also cause neuromuscular blockade via direct membrane stabilization and calcium channel inhibition. This additive pharmacodynamic interaction can lead to prolonged or enhanced muscle weakness, potentially resulting in respiratory paralysis and apnea. Clinically, this combination increases the risk of acute respiratory failure and may prolong recovery from neuromuscular blockade."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HUMATIN vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, answered by our medical review team.
HUMATIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is a Aminoglycoside Antibiotic that works by Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HUMATIN and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HUMATIN is: 15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.. The standard adult dose of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is: Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HUMATIN and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HUMATIN is classified as Category C. FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational . BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is classified as Category A/B. No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.